Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2893370 | 1.00 | MCHR1 (0.67) | MCHR1KCNH2HRH3MAOAMAOB | |
| SCHEMBL2890980 | 0.90 | MCHR1 (0.62) | MCHR1KCNH2HRH3MAOBLTA4H | |
| SCHEMBL2890977 | 0.90 | MCHR1 (0.62) | MCHR1KCNH2HRH3MAOBLTA4H | |
| SCHEMBL2887071 | 0.89 | MCHR1 (0.74) | MCHR1KCNH2HRH3LTA4HMAPK14 | |
| SCHEMBL2887074 | 0.89 | MCHR1 (0.74) | MCHR1KCNH2HRH3LTA4HMAPK14 | |
| SCHEMBL2891931 | 0.89 | MCHR1 (0.58) | MCHR1KCNH2HRH3MAOBLTA4H | |
| SCHEMBL2891930 | 0.89 | MCHR1 (0.58) | MCHR1KCNH2HRH3MAOBLTA4H | |
| SCHEMBL2892262 | 0.89 | LTA4H (0.69) | MCHR1KCNH2HRH3LTA4HMAPK14 | |
| SCHEMBL2887179 | 0.89 | LTA4H (0.69) | MCHR1KCNH2HRH3LTA4HMAPK14 | |
| SCHEMBL2890476 | 0.89 | MCHR1 (0.55) | MCHR1KCNH2HRH3MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732456-B2 | Pyridone derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732456-B2 | Pyridone derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732456-B2 | Pyridone derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20070208046-A1 | Pyridone derivative | MSD K.K. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070208046-A1 | Pyridone derivative | MSD K.K. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070208046-A1 | Pyridone derivative | MSD K.K. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1741703-A1 | PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208046-A1 | Pyridone derivative | CHRM1, XDH, MTR | MCHR1 535/4885KCNH2 1619/4885HRH3 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.